Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06080373

CBT for Adult Inmates With ADHD

Background Recent literature suggests that ADHD is a risk factor for the development of antisocial behavior that is more severe and persistent than in community and other psychiatric populations. The combination of stimulant medication and psychotherapy (particularly cognitive-behavioral therapy, CBT) is considered an evidence-based intervention for adults with ADHD. In contrast, few studies have evaluated the efficacy of medication in adult prisoners with ADHD, and the literature on the efficacy of psychotherapy is virtually nonexistent. Therefore, this article presents the protocol of a trial that will assess the efficacy of a formulation-based CBT program for inmates with ADHD.

Methods The study has a multicenter randomized controlled trial design. After screening and recruitment, participants will be randomly assigned to the CBT intervention, a general offender treatment program, or a waitlist. Pre- and post-treatment self-report and clinician-report assessments, as well as 6- and 12-month follow-up assessments will be conducted. These will include both clinical (e.g., ADHD symptoms, depression and anxiety symptoms, self-esteem, alcohol/drug abuse, treatment adherence, quality of life) and criminological (e.g., recidivism and risk of recidivism) measures. Linear mixed models will be used to assess differences between groups.

Discussion This study may be the first to evaluate the efficacy of a psychotherapy intervention in adult inmates with ADHD. It is expected that addressing the specific needs of ADHD would not only result in the previously reported clinical improvements (e.g., reduction in ADHD and comorbidity symptoms), but also reduce the risk and rate of recidivism compared to the general intervention or no intervention. However, the design may be limited by the difficulties inherent in the prison setting and in following up the sample after release.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • To have signed written informed consent to participate in the study
  • To be between 18 and 65 years of age
  • To meet the DSM-5 diagnostic criteria for ADHD (American Psychiatric Association, 2013)
  • To have been convicted of at least one crime under Spanish or German criminal law
  • To have been incarcerated for at least six months and three or fewer years since the completion of the conviction at the time of eligibility assessment.

Exclusion criteria

  • To have a severe personality disorder, psychotic disorder, or pervasive developmental disorder as their primary diagnosis, as the intervention would not meet their clinical needs
  • To have an IQ of 80 or less, as measured by a standardized IQ test (Raven et al., 1993), due to the complexity of the cognitive components in the CBT program
  • To have participated in a previous psychological intervention for ADHD;
  • To not be fluent in Spanish or German, depending on the study site.

Treatment and study plan

PROBECO

Behavioral

Spanish participants in the active control group will undergo the PROBECO program, designed by the Spanish Penitentiary Agency for various violent crimes. It aims to eradicate criminal behavior, reduce recidivism, and teach social skills. It has four phases.

German participants will be placed in social therapeutic facilities for compulsory psychotherapy focused on relapse prevention.

Formulation-based cognitive behavioral therapy

Behavioral

The CBT program includes these core modules:

A. ADHD Psychoeducation: Provides information on ADHD characteristics, neurobiology, treatments, and their efficacy. Shared with a significant other if available.

B. Planning Skills and Distraction Management: Teaches time management, task prioritization, and distraction control techniques.

C. Cognitive Restructuring: Based on Ellis' Rational Behavioral Emotive Therapy, it helps participants identify and modify irrational thoughts for better emotional regulation.

D. Maintenance of Treatment Gains: Reviews progress, identifies risk factors, and develops action plans for post-treatment challenges.

Primary outcomes

  1. Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID)

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This is considered one of the primary outcomes. The CAADID is a structured interview divided into two parts. Part I may be self-administered or clinician-administered and collects information on the subject's demographic history, developmental history, associated risk factors, and comorbidity, while Part II must be administered by a trained clinician and assesses DSM-IV criteria for ADHD in adults. Only Part II will be used for the study, as information on patient history is not relevant for measuring response to interventions.

  2. Reoffending rate

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This will be the primary criminological outcome. Police records will be checked every 6 months after the end of treatment to look for new arrests. We will also try to check court and prison records for new convictions and incarcerations. However, access to this information may be very limited in European criminal justice systems, so it may be difficult to obtain.

Secondary outcomes

  1. Clinical Global Impression (CGI)

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    Is a three-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. It is a widely used, robust measure of efficacy in clinical trials. The global functioning outcome provides a measure of the impact that symptoms have on daily functioning in life domains (e.g., social, family, work, personal, and academic, among others).

  2. Attention-deficit/hyperactivity rating scale-IV

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This measure will be the primary self-reported outcome. The scale includes 18 items that reference DSM-IV criteria (American Psychiatric Association, 2000), and it is used to determine the presence and severity of current ADHD symptoms. Each item is scored from 0 (never, rarely) to 3 (often). This measure has high validity and reliability and has been widely used both for clinical and research purposes.

  3. Rosenberg self-esteem scale (RSES

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This 10-item scale provides a unidimensional measure of global self-esteem and acceptance of self-worth.

  4. Adult ADHD Quality of Life Questionnaire (AAQoL

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    It is an ecologically valid measure of the quality of life designed specifically for adults with ADHD. It consists of 29 items corresponding to four domains particularly relevant for patients with ADHD: productivity, psychological health, social relationships, and life perspectives.

  5. Maudsley Addiction Profile (MAP)

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This is a 60-item, multidimensional instrument for assessing treatment outcome in people with drug and/or alcohol problems.

  6. Beck depression inventory-II (BDI-II) and Beck anxiety inventory (BAI)

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    These are one of the most commonly used self-report instruments to assess the severity of depressive and anxiety symptoms, respectively. A total score is obtained from the sumo of its 21 items, with higher scores indicating higher levels of depression or anxiety.

  7. Historical Clinical Risk Management-20 (HCR-20)

    Time frame: Pre and post-treatment plus follow-up assessments 6 and 12 months after the end of the intervention

    This instrument is a guide to predicting violence risk in inmates and psychiatric patients, providing a probabilistic prediction of the risk of future antisocial behavior. A trained rater must assess the presence of 20 past, present, and future risk factors organized into three different scales. The HCR-20 includes both dynamic and static risk factors. Three levels of risk can be identified without initial reference to explicit tables, scales, or cutoff points: low, moderate, or high (and imminent).

Other outcomes

  1. Treatment adherence

    Time frame: During the intervention

    In order to measure adherence more objectively, attendance at treatment sessions and completion of homework assignments are systematically recorded by the therapist at each session.

Study contacts

Contact information is provided by the study sponsor or research team.

Carlos López-Pinar, Dr

CONTACT

[email protected]

+34 665878367

Sponsors and collaborators

Lead sponsor

Universidad Europea de Valencia

Other

Registry information

Official study title

Formulation-Based Cognitive-Behavioral Therapy Compared to an Active Control and a Waitlist in Adult Inmates With ADHD: A Randomized Controlled Trial

Important dates

Study start
2027
Primary completion
2028
Study completion
2029
First posted
Oct 12, 2023
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.